Results 71 to 80 of about 1,206 (142)

Patient-Centric Design of the Lonapegsomatropin Auto-Injector for Growth Hormone Deficiency: Usability Validation of Safe and Effective Use. [PDF]

Med Devices (Auckl)
Lau M, Fabricius PE, Madsen NB, Egesborg H, Jensen J.   +4 more
europepmc   +1 more source

Persistence with daily growth hormone among children and adolescents with growth hormone deficiency in Japan. [PDF]

PLoS One
Loftus J, Wogen J, Benjumea D, Jhingran P, Chen Y, Alvir J, Wajnrajch MP, Takasawa K.   +7 more
europepmc   +1 more source

Long-acting GH Use in Patients With Adult GH Deficiency Coexisting With Type 1 Diabetes Mellitus. [PDF]

JCEM Case Rep
Higuchi Y, Bando H, Yamamoto M, Hirota Y, Ogawa W, Fukuoka H.   +5 more
europepmc   +1 more source

Somatropin [PDF]

, 2020
openaire   +1 more source

Two-year real-world experience with somatrogon in children and adolescents with growth hormone deficiency. [PDF]

Front Endocrinol (Lausanne)
Tamaro G, Rodaro C, Fachin A, Fabretto A, Tornese G.   +4 more
europepmc   +1 more source

Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results.

J Clin Endocrinol Metab
Biller BMK, Gilis-Januszewska A, Doknic M, Pico AM, Fleseriu M, Raverot G, Isidori AM, Takahashi Y, Garcia JM, Silverstein JM, Bancos I, Fukuoka H, Huang E, Kang J, Komirenko AS, Domrzalski L, Shu AD, Beckert M, Yuen KCJ.   +18 more
europepmc   +1 more source

A real-world investigation of drug-induced hyperglycemia and diabetes mellitus in pediatric populations using the FDA adverse event reporting system. [PDF]

Front Med (Lausanne)
Zhao X, Sun X, Ma M, Teng L, Qu X.
europepmc   +1 more source

Once-Weekly Lonapegsomatropin Was Efficacious and Well Tolerated in Chinese Children with Growth Hormone Deficiency: Results from a Phase 3 Randomized Trial.

Horm Res Paediatr
Ying Y, Wei H, Zhong Y, Li Y, Yang Y, Li G, Gu W, Cheng X, Gong C, Xu X, Zhang H, Fu J, Yao H, Zhou L, Ge X, Li T, Zhu S, Wang Y, Li J, Li Y, Luo X.   +20 more
europepmc   +1 more source

Temporal Trends in the Prescription of Biosimilars and the Status of Switching from Original Biologics to Biosimilars at Individual and Institutional Levels in Japan. [PDF]

Ther Innov Regul Sci
Matsumoto M, Kumazawa R, Ishii-Watabe A, Horiguchi I, Mamiya H, Shibata H, Saito Y, Adomi M, Taniguchi Y, Komiyama J, Sakai R, Iwagami M.   +11 more
europepmc   +1 more source

Effect of a financial incentive scheme on promoting prescription of biosimilars: a interrupted time-series analyses. [PDF]

Ann Clin Epidemiol
Morita T, Sasabuchi Y, Yasunaga H.
europepmc   +1 more source